Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immunotherapies - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Next Previous
Drug Profile

Research programme: immunotherapies - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Alternative Names: Immuno-oncology therapeutics - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune-Onc Therapeutics; University of Texas Health Science Center at Houston; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Leukocyte-associated immunoglobulin-like receptor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Immunological disorders

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 12 Mar 2020 No development reported for Immunological disorders in USA (Parenteral)
  • 12 Mar 2020 Preclinical trials in Cancer in USA (Parenteral) before March 2020 (Immune-Onc Therapeutics pipeline March 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top